Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of the formula:



(I)

OR



(II)

OR



(III)

OR



(IV)

OR



(V)

OR



(VI)

OR



(VII)

OR



(VIII)

wherein:

R^1 is selected from the group of hydrogen, F, Cl, Br, I, NO_2, OR^{12}, SR^{12}, SOR^{12}, SO_2R^{12}, $NR^{12}R^{13}$, C_1-C_8 alkyl, C_1-C_8 haloalkyl and C_1-C_8 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are ~~may be~~are optionally substituted;

R^2 is selected from the group of ~~hydrogen,~~ F, Cl, Br, I, CH_3, CF_3, CHF_2, CH_2F, CF_2Cl, CN, CF_2OR^{12}, CH_2OR^{12}, OR^{12}, SR^{12}, SOR^{12}, SO_2R^{12}, $NR^{12}R^{13}$, [[C_1-C_8]]C_2-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkenyl and C_2-C_8 alkynyl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl and alkynyl groups are ~~may be~~are optionally substituted;

R^3 through R^8 each independently is selected from the group of hydrogen, F, Cl, Br, I, OR^{12}, $NR^{12}R^{13}$, SR^{12}, SOR^{12}, SO_2R^{12}, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkynyl, C_2-C_8 alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups are ~~may be~~are optionally substituted; or

R^3 and R^5 taken together form a bond; or

R^5 and R^7 taken together form a bond; or

R^4 and R^6 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may~~is optionally substituted; or

R^6 and R^8 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may~~is optionally substituted;

R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, CN, OR^{12}, $NR^{12}R^{13}$, $C_m(R^{12})_{2m}OR^{13}$, SR^{12}, SOR^{12}, SO_2R^{12}, $NR^{12}C(O)R^{13}$, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups ~~may be~~are optionally substituted;

R^{11} is selected from the group of, F, Br, Cl, I, CN, OR^{14}, $NR^{14}R^{13}$, and SR^{14};

R^{12} and R^{13} each independently is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~are optionally substituted;

R^{14} is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, aryl, heteroaryl, $C(O)R^{15}$, CO_2R^{15} and $C(O)NR^{15}R^{16}$, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups ~~may be~~are optionally substituted;

R^{15} and R^{16} each independently is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted;

W is O or S;

X is $N\{R^{14}\}$;

Y is selected from the group of O, S, $N\{R^{12}\}$, and $NO\{R^{12}\}$;

Z is $N\{R^{12}\}$;

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

2. (currently amended) A compound according to claim 1, wherein R^2 is selected from the group of ~~hydrogen,~~ F, Cl, Br, CF_3, CF_2Cl, CF_2H, CFH_2, [[C_1-C_6]]C_2-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

3. (original) A compound according to claim 1, wherein R^2 is selected from the group of CF_2OR^{12}, CH_2OR^{12}, OR^{12}, SR^{12}, SOR^{12}, SO_2R^{12} and $NR^{12}R^{13}$.

4. (currently amended) A compound according to claim 1, wherein R^2 is selected from the group of ~~hydrogen,~~ F, Cl, Br, CF_3, CF_2Cl, CF_2H, CFH_2, [[C_1-C_4]]C_2-C_4 alkyl, C_1-C_4 haloalkyl, C_1-C_4 heteroalkyl, C_2-C_4 alkenyl and C_2-C_4 alkynyl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl and alkynyl groups ~~may be~~are optionally substituted.

5. (currently amended) A compound according to claim 4, wherein R^2 is selected from the group of ~~hydrogen,~~ F, Cl, CF_3, CF_2Cl, CF_2H, CFH_2 and optionally substituted [[C_1-C_4]]C_2-C_4 alkyl.

6. (currently amended) A compound according to claim 1, wherein R^9 and R^{10} each independently is selected from hydrogen, F, Cl, Br, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

7. (currently amended) A compound according to claim 6, wherein R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, $C_1 - C_4$ alkyl, $C_1 - C_4$ haloalkyl and $C_1 - C_4$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

8. (original) A compound according to claim 7, wherein R^9 and R^{10} each independently is selected from the group of hydrogen, F and CH_3.

9. (currently amended) A compound according to claim 1, wherein R^1 is selected from the group of hydrogen, F, Cl, Br, I, $C_1 - C_6$ alkyl, $C_1 - C_6$ haloalkyl and $C_1 - C_6$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

10. (currently amended) A compound according to claim 9, wherein R^1 is selected from the group of hydrogen, F, Cl, $C_1 - C_4$ alkyl, $C_1 - C_4$ haloalkyl and $C_1 - C_4$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

11. (original) A compound according to claim 9, wherein R^1 is hydrogen or F.

12. (currently amended) A compound according to claim 1, wherein Y ~~and W each independently~~ is O or S.

13. (original) A compound according to claim 12, wherein Y and W are each O.

14. (currently amended) A compound according to claim 1, wherein R^{11} is selected from the group of F, ~~Br,~~ Cl, CN, OR^{14}, $NR^{14}R^{13}$, and SR^{14}.

15. (previously presented) A compound according to claim 14, wherein R^{11} is selected from the group of F, Cl, OR^{14}, SR^{14}, and $NR^{14}R^{13}$.

16. (previously presented) A compound according to claim 15, wherein R^{11} is selected from the group of Cl, OR^{14} and SR^{14}.

17. (original) A compound according to claim 16, wherein R^{11} is OR^{14}.

18. (cancelled)

19. (cancelled)

20. (cancelled)

21. (cancelled)

22. (cancelled)

23. (currently amended) A compound according to claim 1, wherein R^{12} is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 heteroalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~are optionally substituted.

24. (currently amended) A compound according to claim 23, wherein R^{12} is selected from the group of hydrogen, C_1-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

25. (currently amended) A compound according to claim 1, wherein R^{13} is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 heteroalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~are optionally substituted.

26. (currently amended) A compound according to claim 25, wherein R^{13} is selected from the group of hydrogen, C_1-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

27. (cancelled)

28. (cancelled)

29. (cancelled)

30. (currently amended) A compound according to claim 1, wherein R^3 and R^4 each independently is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted; or

R^3 and R^5 taken together form a bond; or

R^4 and R^6 taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~are optionally substituted.

31. (currently amended) A compound according to claim 30, wherein R^3 and R^4 each independently is selected from the group of hydrogen, C_1-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

32. (currently amended) A compound according to claim 1, wherein R^5 and R^7 each independently is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted; or

R^5 and R^7 taken together form a bond.

33. (currently amended) A compound according to claim 32, wherein R^5 and R^7 each independently is selected from the group of hydrogen, C_1-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

34. (currently amended) A compound according to claim 1, wherein R^6 and R^8 each independently is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups ~~may be~~are optionally substituted; or

R^6 and R^8 taken together form a three to eight membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~are optionally substituted.

35. (currently amended) A compound according to claim 34, wherein R^6 and R^8 each independently is selected from the group of hydrogen, $C_1 - C_4$ alkyl, $C_1 - C_4$ haloalkyl, $C_1 - C_4$ heteroalkyl, heteroaryl and aryl, wherein alkyl, haloalkyl, heteroaryl and aryl ~~may be~~are optionally substituted; or

R^6 and R^8 taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~are optionally substituted.

36. (currently amended) A compound according to claim 1, wherein:

R^1 is selected from the group of hydrogen, F, Cl, Br, I, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted;

R^2 is selected from the group of ~~hydrogen,~~ F, Cl, Br, CF_3, CF_2Cl, CF_2H, CFH_2, [[C_1-C_6]]C_2-C_6 alkyl; C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted; and

R^3 and R^4 each independently is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

37. (currently amended) A compound according to claim 36, wherein:

R^5 through R^8 each independently is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted; or

R^6 and R^8 taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may be~~are optionally substituted.

38. (currently amended) A compound according to claim 37, wherein:

R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted;

R^{12} is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~are optionally substituted; and

R^{14} is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 heteroalkyl, $C(O)R^{15}$, CO_2R^{15} and $C(O)NR^{15}R^{16}$, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

39. (previously presented) A compound according to claim 38, wherein

Y is O or S.

40. (currently amended) A compound according to claim 1, wherein said compound is selected from the group of:

6-Methyl-4-trifluoromethyl-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Isopropyl-6-methyl-4-trifluoromethyl-7H-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Allyl-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-(4-Methoxyphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

4-Trifluoromethyl-5,6,7,8-tetrahydrocyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

4-Trifluoromethyl-5,6,7,8,9,10-hexahydrocycloheptano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-6,6a,7,8,9,9a(cis)-Hexahydro-6-trifluoroethyl-4-trifluoromethylcyclopentano-[i]pyrrolo[2,3-g]quinolin-2(1H)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-6,6a,7,8,9,9a(cis)-Hexahydro-6-ethyl-4-trifluoromethylcyclopentano-[i]pyrrolo[2,3-g]quinolin-2(1H)-one;

(±)-5,6-Dihydro-5,6-*cis*-dimethyl-7-trifluoroethyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-7,8-Dihydro-7,8-cis-dimethyl-6-trifluoroethyl-4-trifluoromethyl-6H-pyrrolo[2,3-g]quinolin-2(1H)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[g]pyrrolo-[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(3-furanylmethyl)-4-trifluoromethyl-cyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(3-thiophenemethyl)-4-trifluoromethyl-cyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2-methylpropyl)-4-trifluoromethyl-cyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2,2,2-chlorodifluoroethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethyl-cyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2,2-dimethoxyethyl)-4-trifluoromethyl-cyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,8,8a(*cis*)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9H-cyclohexano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,8,9,9a(*cis*),10-Octahydro-10-(2,2,2-trifluoroethyl)-4-trifluoromethyl-cycloheptano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-5-(4-nitrophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-5-(4-dimethylaminophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-5-(3-trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-5-(4-fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5-phenyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2-dimethoxyethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-5-isopropyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5-(2-ethoxycarbonylethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

~~6-Ethyl-5-methyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;~~

~~(±) 5,6-*cis*-Dihydro-5-methyl-6-ethyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;~~

5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

~~6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;~~

6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5,6,7,8-Tetrahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

8-Trifluoroethyl-4-trifluoromethyl-6,8-dihydrocyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

9-Trifluoroethyl-4-trifluoromethyl-9*H*-benzo[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Trifluoroethyl-4-trifluoromethyl-6,7,8,9-tetrahydrocyclopetano[i]pyrrolo[2,3-g]quinolin-2(1H)-one;

5-(3-Trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-(4-Fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-(2-Ethoxycarbonylethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

7-Ethyl-8-methyl-6-(2,2,2-trifluoroethyl)-4-trifluoromethyl-6H-pyrrolo[2,3-g]quinolin-2(1H)-one;

5-Hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Methyl-6-(1-hydroxyethyl)-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Methyl-6-acetyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Formyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Acetyloxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

2-Acetyloxy-5-hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinoline;

6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Ethoxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(+)-6-(1-Methoxyethyl)-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

7-Allyl-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

6-Ethyl-7-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

7-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

7-(2-Hydroxyethyl)-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

(+)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(–)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-f]quinolin-2(1H)-one;

(±)-5,6-Dihydro-7-ethyl-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-f]quinolin-2(1H)-one;

7,8-Dihydro-6-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;

6-(2,2,2-Trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;

8-Chloro-6-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;

5-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[3,2-f]quinolin-2(1H)-one;

6-Formyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one; and

5,6-Dimethyl-7-(2,2-difluorovinyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one.

41. (previously presented) A compound according to claim 1, wherein said compound is selected from the group of:

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-6,6a,7,8,9,9a(cis)-Hexahydro-6-trifluoroethyl-4-trifluoromethylcyclopentano-[i]pyrrolo[2,3-g]quinolin-2(1H)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5,6-*cis*-dimethyl-7-trifluoroethyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-7,8-Dihydro-7,8-cis-dimethyl-6-trifluoroethyl-4-trifluoromethyl-6H-pyrrolo[2,3-g]quinolin-2(1H)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[g]pyrrolo-[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2,2,2-chlorodifluoroethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethyl-cyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-4c,5,6,7,8,8a(*cis*)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9H-cyclohexano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6- *cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(±)-5,6-*cis*-Dihydro-5-methyl-6-ethyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5,6,7,8-Tetrahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Trifluoroethyl-4-trifluoromethyl-6,7,8,9-tetrahydrocyclopetano[i]pyrrolo[2,3-g]quinolin-2(1H)-one;

7-Ethyl-8-methyl-6-(2,2,2-trifluoroethyl)-4-trifluoromethyl-6H-pyrrolo[2,3-g]quinolin-2(1H)-one;

6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(+)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one; and

(–)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one.

42. (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula:



(I)

OR



(II)

OR



(III)

OR



(IV)

OR



(V)

OR



(VI)

OR



(VII)

OR



(VIII)

wherein:

R^1 is selected from the group of hydrogen, F, Cl, Br, I, NO_2, OR^{12}, SR^{12}, SOR^{12}, SO_2R^{12}, $NR^{12}R^{13}$, C_1-C_8 alkyl, C_1-C_8 haloalkyl and C_1-C_8 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted;

R^2 is selected from the group of ~~hydrogen,~~ F, Cl, Br, I, CH_3, CF_3, CHF_2, CH_2F, CF_2Cl, CN, CF_2OR^{12}, CH_2OR^{12}, OR^{12}, SR^{12}, SOR^{12}, SO_2R^{12}, $NR^{12}R^{13}$, [[C_1-C_8]]C_2-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkenyl and C_2-C_8 alkynyl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl and alkynyl groups ~~may be~~are optionally substituted;

R^3 through R^8 each independently is selected from the group of hydrogen, F, Cl, Br, I, OR^{12}, $NR^{12}R^{13}$, SR^{12}, SOR^{12}, SO_2R^{12}, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkynyl, C_2-C_8 alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl,

haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups ~~may be~~are optionally substituted; or

R^3 and R^5 taken together form a bond; or

R^5 and R^7 taken together form a bond; or

R^4 and R^6 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may~~is optionally substituted; or

R^6 and R^8 taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may~~is optionally substituted;

R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, CN, OR^{12}, $NR^{12}R^{13}$, $C_m(R^{12})_{2m}OR^{13}$, SR^{12}, SOR^{12}, SO_2R^{12}, $NR^{12}C(O)R^{13}$, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups ~~may be~~are optionally substituted;

R^{11} is selected from the group of, F, Br, Cl, I, CN, OR^{14}, $NR^{14}R^{13}$, and SR^{14};

R^{12} and R^{13} each independently is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~are optionally substituted;

R^{14} is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, aryl, heteroaryl, $C(O)R^{15}$, CO_2R^{15} and $C(O)NR^{15}R^{16}$, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups ~~may be~~are optionally substituted;

R^{15} and R^{16} each independently is selected from the group of hydrogen, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted;

W is O or S;

X is $N\{R^{14}\}$;

Y is selected from the group of O, S, $N\{R^{12}\}$, and $NO\{R^{12}\}$;

Z is $N\{R^{12}\}$;

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

43. (original) A pharmaceutical composition according to claim 42, wherein the carrier is suitable for enteral, parenteral, suppository, or topical administration.

44. (currently amended) A pharmaceutical composition according to claim 42, wherein R^1 is selected from the group of hydrogen, F, Cl, Br, I, $C_1 - C_6$ alkyl, $C_1 - C_6$ haloalkyl and $C_1 - C_6$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

45. (currently amended) A pharmaceutical composition according to claim 44, wherein R^1 is selected from the group of hydrogen, F, Cl, $C_1 - C_4$ alkyl, $C_1 - C_4$ haloalkyl and $C_1 - C_4$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

46. (currently amended) A pharmaceutical composition according to claim 42, wherein R^2 is selected from the group of hydrogen, F, Cl, Br, CF_3, CF_2Cl, CF_2H, CFH_2, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

47. (currently amended) A pharmaceutical composition according to claim 46, wherein R^2 is selected from the group of ~~hydrogen,~~ F, Cl, Br, CF_3, CF_2Cl, CF_2H, CFH_2, [[C_1-C_4]]C_2-C_4 alkyl, C_1-C_4 haloalkyl and C_1-C_4 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

48. (currently amended) A pharmaceutical composition according to claim 42, wherein R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, $C_1 - C_6$ alkyl, $C_1 - C_6$ haloalkyl and $C_1 - C_6$ heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

49. (original) A pharmaceutical composition according to claim 48, wherein R^9 and R^{10} each independently is selected from the group of hydrogen, F and CH_3.

50. (currently amended) A pharmaceutical composition according to claim 42, wherein R^{11} is selected from the group of F, ~~Br,~~ Cl, CN, OR^{14}, $NR^{14}R^{13}$, and SR^{14}.

51. (previously presented) A pharmaceutical composition according to claim 50, wherein R^{11} is selected from the group of F, Cl, OR^{14}, SR^{14} and $NR^{14}R^{13}$.

52. (currently amended) A pharmaceutical composition according to claim 42, wherein Y ~~and W each independently~~ is O or S.

53. (cancelled)

54. (cancelled)

55. (currently amended) A pharmaceutical composition according to claim 42, wherein R^{12} is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 heteroalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~are optionally substituted.

56. (cancelled)

57. (currently amended) A pharmaceutical composition according to claim 42, wherein R^3 and R^4 each independently is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted; or

R^3 and R^5 taken together form a bond; or

R^4 and R^6 taken together form a four to six membered carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may~~is optionally substituted.

58. (currently amended) A pharmaceutical composition according to claim 42, wherein R^5 and R^7 each independently is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted; or

R^5 and R^7 taken together form a bond.

59. (currently amended) A pharmaceutical composition according to claim 42, wherein R^6 and R^8 each independently is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups ~~may be~~are optionally substituted; or

R^6 and R^8 taken together form a three to eight membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may~~is optionally substituted.

60. (currently amended) A pharmaceutical composition according to claim 42, wherein:

R^1 is selected from the group of hydrogen, F, Cl, Br, I, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted;

R^2 is selected from the group of hydrogen, F, Cl, Br, CF_3, CF_2Cl, CF_2H, CFH_2, C_1-C_6 alkyl; C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted; and

[[R3]]R^3 and [[R4]]R^4 each independently is selected from the group of hydrogen, [[C1-C6]]C_1-C_6 alkyl, [[C1-C6]]C_1-C_6 haloalkyl and [[C1-C6]]C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

61. (currently amended) A pharmaceutical composition according to claim 60, wherein:

R^5 through R^8 each independently is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted; or

R^6 and R^8 taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring ~~may~~is optionally substituted.

62. (currently amended) A pharmaceutical composition according to claim 61, wherein:

R^9 and R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted;

R^{12} is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 heteroalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups ~~may be~~are optionally substituted; and

R^{14} is selected from the group of hydrogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 heteroalkyl, $C(O)R^{15}$, CO_2R^{15} and $C(O)NR^{15}R^{16}$, wherein the alkyl, haloalkyl and heteroalkyl groups ~~may be~~are optionally substituted.

63. (currently amended) A pharmaceutical composition according to claim 62, wherein[[:]] Y is O or S.

64. (withdrawn) A method of treating an individual having a condition mediated by an androgen receptor comprising administering to said individual a pharmaceutically effective amount of a compound according to any one of claims 1, 40 or 41.

65. (withdrawn) A method according to claim 64, wherein said compound is represented by formula (I).

66. (withdrawn) A method according to claim 64, wherein said compound is represented by formula (II).

67. (withdrawn) A method according to claim 64, wherein said compound is represented by formula (III).

68. (withdrawn) A method according to claim 64, wherein said compound is represented by formula (IV).

69. (withdrawn) A method according to claim 64, wherein said compound is represented by formula (V).

70. (withdrawn) A method according to claim 64, wherein said compound is represented by formula (VI).

71. (withdrawn) A method according to claim 64, wherein said compound is represented by formula (VII).

72. (withdrawn) A method according to claim 64, wherein said compound is represented by formula (VIII).

73. (withdrawn) A method according to claim 64, wherein said condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.

74. (withdrawn) A method according to claim 64, wherein said condition is alleviated with a therapy selected from the group of male hormone replacement therapy, female androgen replacement therapy and stimulation of hematopoiesis.

75. (withdrawn) A method of modulating an androgen receptor in an individual comprising administering an androgen receptor modulating effective amount of a compound according to any one of claims 1, 40 or 41.

76. (withdrawn) A method according to claim 64, wherein said individual has a condition mediated by an androgen receptor

77. (withdrawn) A method according to claim 76, wherein said condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.

78. (withdrawn) A method according to claim 76, wherein said condition is alleviated with a therapy selected from the group of male hormone replacement therapy, female androgen replacement therapy and stimulation of hematopoiesis.

79. (withdrawn) A method according to claim 75, wherein said modulation is activation.

80. (withdrawn) A method according to claim 76, wherein said individual has a condition mediated by an androgen receptor.

81. (withdrawn) A method according to claim 80, wherein said condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.

82. (withdrawn) A method according to claim 80, wherein said condition is alleviated with a therapy selected from the group of male hormone replacement therapy, female androgen replacement therapy and stimulation of hematopoiesis.

83. (withdrawn) A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 100 nM.

84. (withdrawn) A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 50 nM.

85. (withdrawn) A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 20 nM.

86. (withdrawn) A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 10 nM.

87. (withdrawn) A method according to claim 75, wherein said modulation is inhibition.

88. (withdrawn) A method according to claim 87, wherein said individual has a condition mediated by an androgen receptor.

89. (withdrawn) A method according to claim 88, wherein said condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.

90. (withdrawn) A method according to claim 88, wherein said condition is alleviated with a therapy selected from the group of male hormone replacement therapy, female androgen replacement therapy and stimulation of hematopoiesis.

91. (withdrawn) A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 100 nM.

92. (withdrawn) A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 50 nM.

93. (withdrawn) A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 20 nM.

94. (withdrawn) A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 10 nM.

95. (withdrawn) A method of treating cancer, comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims 1, 40 or 41.

96. (withdrawn) A method of determining the presence of an androgen receptor (AR) in a cell or cell extract comprising: (a) labeling a compound according to any one of claims 1, 40 or 41; (b) contacting the cell or cell extract with said labeled compound; and (c) testing the contacted cell or cell extract to determine the presence of AR.

97. (withdrawn) A method for purifying a sample containing an androgen receptor *in vitro*, comprising: (a) contacting said sample with a compound according to any one of claims 1, 40 or 41; (b) allowing said compound to bind to said androgen receptor to form a bound compound/receptor combination; and (c) isolating said bound compound/receptor combination.